News Archive

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

Joint study will accelerate development of physiologically relevant 3D models for anti-cancer drug screening.  PDF Version

 

Schlieren, Switzerland -  May 03, 2017  InSphero AG today announced a collaboration with the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to identify anti-cancer agents with cytotoxic activity in 3D tumor models. In this joint project, NCATS will use patient-derived xenograft (PDX) tumor microtissues, provided by InSphero in its 384 well platform, to screen a library of anti-cancer agents for anti-tumor efficacy using assays that measure cell proliferation, tissue integrity, and tissue size.

“For cancer drug discovery, it is of critical importance to have models that are physiologically relevant,” says InSphero Chief Technology Officer and Co-founder Jens M. Kelm, Ph.D. “3D microtissues models provide a more accurate reflection of the tumor and its extracellular environment.” The latest generation of customizable 3D tumor microtissue models available from InSphero also capture the heterogeneity of tumor cell populations, making them ideal for investigating special tumor cell sub-populations called cancer stem cells (CSCs) or tumor-initiating cells. These cells have self-renewal potential and are thought to drive tumor formation and metastasis. CSCs appear to be resistant to current chemotherapy and radiation-therapy treatments that produce cancer recurrence, thus there is a heightened interest among oncologists to be able to screen therapeutic agents that target CSCs and other tumor cell sub-populations.

“To unlock the full potential of more physiologically relevant models to fosterfor drug development we need to be able to integrate 3D cancer models into the drug screening process as early as possible,” says Dr. Kelm. InSphero will work closely with researchers at NCATS to evaluate how PDX-derived tumor microtissues can be applied in primary and secondary screening campaigns using small to mid-size compound libraries.

“Our project with InSphero is yet another example of how NCATS fosters collaborations to explore novel technologies that carry the promise to accelerate discovery of molecular therapeutic agents across multiple disease areas,” says Anton Simeonov, Ph.D., acting deputy scientific director of NCATS’ Division of Pre-Clinical Innovation.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

Image

insphero logo


InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

Research effort will use InSphero 3D InSight™ Human Liver Microtissues to develop novel assays to predict and evaluate certain mechanisms that cause drug-induced liver injury (DILI). PDF Vesion

Schlieren, Switzerland - April 27, 2017

InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, has entered into an agreement with Pfizer Inc. (NYSE:PFE), one of the world’s premier biopharmaceutical companies, to develop a novel predictive toxicology assay using InSphero 3D InSight™ Human Liver Microtissues. This novel mechanistic in vitro assay will aim to leverage the enhanced sensitivity and longevity of InSphero 3D liver models that may allow for the multiplexing of several endpoints to help detect and predict mechanisms of drug toxicity.

InSphero CEO and co-founder, Dr. Jan Lichtenberg, says, “Our 3D liver models enable researchers to better predict potential toxicity and side-effects using more biologically relevant cell based assays. These models may also help reduce dependency on animal models, which add significant cost, delay time to market, and often fail to accurately reflect how humans will respond to a drug. We already have a long-standing relationship with Pfizer and this new agreement will enable the development of assays with potentially even greater utility and predictive power for Pfizer’s early drug development."

Dr. Simon Messner, who will lead the project for InSphero adds, “The longevity and organotypic nature of 3D InSight™ Human Liver Microtissues highly correlates to that of native liver, exhibiting appropriate cellular organization, cytochrome P450 enzyme responsiveness, and metabolic functionality. Using this 3D model could result in improved accuracy and precision by which certain DILI mechanisms are predicted in vitro.”

The agreement commences in April 2017 and involves InSphero scientists in the USA (Brunswick, ME) and Schlieren (Switzerland) facilities, with input from Pfizer scientists.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreatic islet, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Image

Microtissue            insphero logo

 

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective of new group. PDF Vesion

Schlieren, Switzerland - April 18, 2017

The inaugural meeting of the 3D Standards Working Group was held during the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC, on Saturday, April 1.  Organized and hosted by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, and InSphero AG, the meeting drew representatives from academic institutions, pharmaceutical and life sciences industries, as well as government agencies, to discuss the use of 3D cancer models within drug discovery campaigns, and review biological and technical requirements needed for the next generation of high-throughput screening-compatible (HTS) models.

"There is a growing need for in vitro 3D tumor models that mimic in vivo tumor physiology for more efficient cancer drug discovery,” says InSphero Chief Scientific Officer Dr. Patrick Guye. “We sought to bring together key opinion leaders in academia, industry and government to develop guidelines that we believe are critical to establish 3D tumor models as a highly predictive platform for therapeutic drug development assays.” The group plans to publish its findings and recommendations for developing and using 3D tumor models for drug development, with the intent to make the best consensus information available to the broader research community.

“We made tremendous progress during this kickoff meeting,” says Dr. Madhu Lal Nag, Head of the Trans NIH RNAi Facility at NCATS. “We not only discussed where we stand today, with regard to developing advanced 3D models that capture the complexity of the tumor microenvironment, but also delved into needs for standardized nomenclature, benchmarking, improved model predictivity, and multiparametric readouts.” Going forward, the group plans to meet quarterly by teleconference and in person during future conferences, such as AACR, which most members of the working group attend.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues (spheroids) driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Image

insphero logo

 

InSphero Wins "Best Technology" Award at ELRIG Research and Innovation Conference

InSphero 3D InSight™ Microtissues Win "Best Technology" Award at ELRIG Research and Innovation Meeting 

Schlieren, Switzerland - March 31, 2017 #ELRIGRI17

InSphero was announced on Thursday as winner of the ELRIG Research & Innovation "Best Technology" Award, recognizing an innovative portfolio of advanced 3D InSight™ Microtissues for drug safety and efficacy testing.  The honor was awarded based on voting by attendees at the annual meeting, held this week at Homerton College in Cambridge, UK.

Amongst the topics of the 2017 scientific program were sessions on the scale-up of physiologically relevant 3D models, as well as innovative technologies for immuno-oncology and immunotherapy. InSphero's patent pending 3D Select™ Process enables industry-scale production of liver, pancreatic islet, and tumor microtissues that more accurately reflect in vivo tissue. InSphero's more physiologically relevant liver microtissues provide a more sensitive and highly specific in vitro model for predicting drug-induced liver injury, while islet and tumor microtissues are advanced models for diabetes and oncology drug discovery. InSphero will present its latest advances in the application of complex 3D tumor/stromal/immune co-culture microtissues for immuno-oncology drug development at next week's American Association of Cancer Research (AACR) Meeting in Washington, DC

Dr. Adrian Rea, who with Dr. Andrea Lindemann accepted the award on behalf of InSphero, stated "We're hononored that our technology was recognized by the attendees at this year's ELRIG Research & Innovation Meeting. We enjoyed the opportunity to discuss the scientific benefits our microtissues have to offer with the attendees, and in turn learn from them about emerging trends in these exciting fields during the scientific sessions" 

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero Liver Microtissue

InSphero 3D InSight™ Human Liver Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to predict drug-induced liver injury in vitro prior to testing in animals or patients.

Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies

Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies 

InSphero presents latest data demonstrating immune cell interaction with 3D tumor models for in vitro efficacy testing of oncology drugs and immunotherapies at AACR.  PDF Version

Schlieren, Switzerland - April 03, 2017 –  InSphero AG highlighted the unique advantages of its physiologically relevant 3D InSight™ Microtissue Platform to drive more efficient development of anti-cancer drugs and immuno-oncology (I-O) approaches at the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC. The presentations included data generated in collaboration with academic, government, and industry partners.

“Our presentations at this year’s AACR meeting display not only the variety and complexity of tumor models we can produce through our Custom Tumor Microtissue Development Service, but also the breadth of applications for which they can be used throughout the drug development pipeline,“ said Dr. Jens Kelm, InSphero Chief Technology Officer and Co-founder. “These range from early discovery screens in cell-line based 3D microtissue models in 384-well format to more complex pre-clinical development and validation studies, using co-cultures of fibroblasts with cancer cell lines or patient-derived xenograft (PDX) samples.”

In addition, InSphero presented data demonstrating the infiltration of activated immune cells, such as peripheral blood mononuclear cells (PBMCs), into tumor-stromal co-culture models. “Recent successes in I-O therapies for blood-borne cancers has triggered the race in pharma for similar strategies targeting solid tumors,” Dr. Kelm said. “Our technology provides the first turnkey 3D platform for mimicking complex solid tumor environments in vitro. It is designed specifically for the development and optimization of CAR-T, CAR-NK, or immunomodulatory based I-O strategies.” InSphero scientists recently showed that activated PBMCs can penetrate tumor-stromal microtissues and specifically kill tumor cells. The findings were published in a collaborative study with Roche Pharmaceutical and ETH Zurich in the January 2017 issue of the journal Cancer Immunology, Immunotherapy.

“We have presented work done in collaboration with the University of Zurich as well, where we’ve created microtissues directly from patient tumor biopsy material,” Dr. Kelm said. “This approach holds potential for in vitro testing in the clinical phase to help identify a personalized treatment plan using drugs most effective against the biopsied material cultured in 3D.”

In addition to custom model development, InSphero offers 3D InSight™ Oncology Services, including single or combinatorial drug testing, tumor relapse, and antibody penetration assays, all of which can be conducted on customized tumor microtissues, or on established tumor-stromal co-culture models. 

InSphero AACR Poster Presentations

Wednesday, April 5 (8 AM – 12 PM)
Poster 5781/17 (Section 38): Establishment of a 3Dex vivoassay as a preclinical drug testing platform for personalized cancer therapy. Presented by Dr. Sumeer Dhar, InSphero AG (collaboration with University of Zurich).

Wednesday, April 5 (8 AM – 12 PM)
5780/16 (Section 38): 3Dex vivoassay platform using primary lung cancer cells in malignant pleural effusions as predictors for clinical outcome of personalized chemotherapy.Presented by Cheng-guang Wu, University of Zurich (collaboration with InSphero AG).

In-booth Poster Presentations

Booth 1029 (Sunday 12 PM – Wednesday 12 PM, during exhibition hours)
- Evaluation of immuno-therapeutic efficacy in biologically relevant 3D tumor microtissue models
- InSphero’s oncology platform for accelerating drug discovery and development

For more information about InSphero 3D InSight™ solutions for oncology, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
Chief Technology Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing

InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing 

Customer and company presentations highlight InSphero 3D InSight™ Liver Microtissues as superior toxicology screening tool. PDF Version

Schlieren, Switzerland - March 27, 2017 – InSphero 3D InSight™ Human Liver Microtissues were identified as a more sensitive, highly specific in vitro model for predicting drug induced liver injury (DILI) and investigating mechanisms of drug toxicity in a series of presentations at the Society of Toxicology’s 56th Annual Meeting (SOT), held in Baltimore, Maryland, March 12-16. InSphero produces 3D liver microtissues using its patent-pending 3D Select™ Process, which yields standardized 3D models that are pre-validated and certified for use in industry-scale in vitro safety and efficacy testing applications.

During the SOT 3D Cell Platforms to Advance Toxicology Sciences workshop, Dr. William Proctor, Head of Investigative Toxicology at Genentech, presented data from an intensive validation study conducted by Genentech and AstraZeneca. The study revealed InSphero Human Liver Microtissues provide twice the sensitivity as traditional primary human hepatocyte (PHH) assays in predicting toxicity of clinically known DILI drugs. Dr. Proctor cited a specific case study in which a blinded compound had shown elevated liver enzymes in Phase I clinical trials in patients. The compound had escaped detection by traditional in vitro screens, but was detected by InSphero 3D InSight™ microtissues at concentrations that reflected clinically relevant dosing levels. Dr. Proctor indicated the model has been instituted in the Genentech group as a secondary (Tier 2) DILI screen.

Commenting on the presentation, InSphero Chief Executive Officer and Co-founder Dr. Jan Lichtenberg, says, ”This study provides convincing evidence that InSphero liver microtissues deliver higher sensitivity without sacrificing specificity. Having two of the world’s leading pharmaceutical companies produce this collaborative, thorough validation further confirms that our 3D models not only reflect in vivo biology, but also deliver the reproducibility and scalability required to meet the early stage screening demands of large pharma. Our assay-ready 3D InSight™ models offer a cost-effective, turn-key solution that gives toxicologists greater confidence when characterizing risk in lead compound sets.”

Additional SOT presentations highlighted the InSphero suite of human and animal-derived liver microtissues for investigative toxicology applications. A novel assay for detecting mitochondrial toxicity was described in collaborative work with Agilent Technologies. Using the Seahorse XFe96 Analyzer to monitor mitochondrial respiration, InSphero 3D InSight™ Human Liver Microtissues displayed a 6-fold increase in spare respiratory capacity compared to 2D PHH, thus providing a significantly larger assay window for detection and classification of mitochondrial liabilities. Oral and poster presentations described the advantages of InSphero rat, monkey, and dog liver microtissues for cross-species analysis of DILI and in vitro mechanistic toxicity studies to reduce the need for costly and ethically charged animal studies.

For more information about InSphero 3D InSight™ Human Liver Microtissues and 3D InSight™ Testing Services, visit www.insphero.com.

 

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero Liver Microtissue

InSphero 3D InSight™ Human Liver Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to predict drug-induced liver injury in vitro prior to testing in animals or patients.

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

3D liver microtissues comprised of cynomolgus hepatocytes provide physiologically relevant in vitro model for investigating species-specific liver toxicity. PDF Version

Schlieren, Switzerland - March 16, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, today announced the launch of 3D InSight™ Monkey Liver Microtissues, further expanding the company’s suite of organotypic 3D liver models for in vitro safety and efficacy testing. Data describing the model’s characterization and application as an alternative to drug testing in animals was presented on Wednesday at the Society of Toxicology’s 56th Annual Meeting and ToxExpo in Baltimore, Maryland.

Drug-induced liver injury (DILI) remains one of the most common causes of late-stage failure in drug development and post-market drug withdrawal. Testing in non-human primates is often required to assess toxicity and potential liver-related side-effects prior to Phase I clinical trials in human patients. 3D InSight™ Monkey Liver Microtissues are a 3D spheroid liver model comprised of primary cynomolgus hepatocytes that serve as an in vitro alternative to in vivo animal tests, enabling testing species-specific effects of a drug on liver function and toxicity in preclinical studies. Viable for more than 28 days in culture, Monkey Liver Microtissues allow long-term drug exposure for predicting DILI and identifying potential mechanisms of toxicity.

InSphero Chief Scientific Officer Dr. Patrick Guye says, “Our 3D monkey liver model addresses the growing trend to reduce or replace the use of animal models in safety testing with more biologically relevant in vitro cell based models. When studies in non-human primates are still required, pre-testing in vitro can help safety and investigative toxicology groups to more effectively plan and minimize the use of costly and ethically charged animal testing. When combined with our human, rat, and dog liver models, our 3D monkey liver microtissues provide toxicologists a more complete toolbox of highly predictive human and animal-derived liver models for in vitro safety testing.”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero monkey liver microtissue histology

InSphero 3D InSight™ Monkey Liver Microtissues serve as an in vitro alternative to pre-clinical animal testing for assessment of drug effects on liver function and toxicity. 

InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

Global leader in 3D cell culture technology to deliver standardized 3D models in new high-throughput, high-content-imaging-optimized format. PDF Version

Schlieren, Switzerland - February 2, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, will debut the GravityTRAP™ 384 Microtissue Platform at the Society for Laboratory Automation and Screening (SLAS) 2017 Conference, February 4-8, in Washington, D.C.

Engineered specifically for 3D microtissue culture, the GravityTRAP™ 384 platform includes two features that differentiate it from existing 384-well plates: distinct microtissue culture and media chambers separated by a tapered SureXchange™ pipetting ledge, providing safe medium aspiration and exchange without accidental loss of microtissues; and a continuous flat-bottomed glass base plate combined with a black-walled body, ensuring superior confocal and high content imaging optics while reducing fluorescent cross-talk between wells. The platform conforms to Society for Biomolecular Screening (SBS) standards and is compatible with state-of-the-art high content imaging and automated liquid handling systems.

“More and more, industry is looking to leverage 3D models that better reflect in vivo biology at earlier stages in drug discovery and development, such as target validation and efficacy screens for potency and selectivity,” said Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder. “However, the current generation of 384-well plates can cause production inconsistencies, complicate handling steps, and decrease the quality and reproducibility of data obtained. These are all critical factors that impact R&D groups overseeing high-throughput screening (HTS) workflows. The GravityTRAP™ 384 Microtissue Platform addresses these issues, providing a plug-and-play solution for HTS. Our customers will receive 384 of our fully qualified, assay-ready 3D InSight™ Microtissues in a plate that is designed for high-content optics and eliminates accidental loss of microtissues during medium exchange steps.”

InSphero will begin delivering microtissues in the GravityTRAP™ 384 format throughout the year, starting with human liver microtissues for early stage drug-induced liver injury (DILI) screening, and multicellular tumor spheroid (MCTS) co-culture models that recreate complex tumor microenvironments for cancer drug screening. In addition to providing assay-ready models in 96- and 384-well formats, Dr. Lichtenberg said that InSphero will offer contract model development services to screening groups that need custom microtissues for specific 384-well projects. “We can assist research teams by doing the 3D model development for them. Our scientific staff is highly experienced in evaluating which cell types readily form microtissues, and they can efficiently create simple, monoculture 3D models, for example from modified tumor cell lines, as well as more complex co-culture models. Our goal is to not only relieve the microtissue and assay development burden, but also long-term sourcing, production and QC costs.”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 GravityTrap 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform enables reproducible production, culture, and high-content imaging of InSphero 3D microtissues in a high-throughput compatible format.

 

GravityTRAP 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform contains distinct microtissue culture and media chambers, separated by a unique SureXchange™ pipetting ledge that prevents accidental microtissue loss during aspiration and medium exchange.

 

 

InSphero Holiday Hours

Happy Holidays from InSphero!
We're looking forward to working with you in 2017

 

Holiday Office Hours

InSphero offices will be closed December 24, 2016 through January 2, 2017.  Any inquiries or orders placed during our holiday break will be processed on Tuesday, January 3.

XMas2016 01 002
 

 

 

Microtissues Production Schedule

 

January Microtissue Production Schedule

To help you plan ahead, here's our January production schedule. For more details, please see our Microtissue Production Schedule.

Order by date ► ships on date to US | EU

3D InSight Human Liver Microtissues

Jan 03 ► Jan 10 | Jan 11

Jan 10 ► Jan 17 | Jan 18

Jan 17 ► Jan 24 | Jan 25

Jan 24 ► Jan 31 | Feb 01

 

3D InSight™ Human Islet Microtissues

Jan 17 ► Jan 24 | Jan 25

 

 

 

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

Dr. Olivier Frey honored by IQ Consortium and AAALAC International for work on microphysiological system to reduce animal-based drug testing. PDF Version

Schlieren, Switzerland - November 3, 2016 – Dr. Olivier Frey of InSphero AG has received the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe, recognizing his pioneering work to integrate advanced 3D microtissue models into microphysiological systems (MPS) for in vitro drug testing. The award was presented to Dr. Frey at the AAALAC International Luncheon, held Wednesday, November 2 in conjunction with the American Association for Laboratory Animal Science (AALAS) 67th National Meeting in Charlotte, North Carolina. 

The Global 3Rs Awards recognize significant innovative contributions toward the advancement of ethical science through the 3Rs of animal research: refinement, replacement, or reduction of animal use. The award selection committee acknowledged Frey’s work to advance MPS technology by interconnecting 3D microtissues derived from human tissues such as liver, heart, endocrine pancreas, or tumor using microfluidic channels to mimic a so-called “Body on a Chip” or BoC. Such systems serve as complex in vitro models used to assess the efficacy or toxicity of a drug in a multi-organ, animal-free system. Frey headed the research, conducted at the ETH Zurich and in collaboration with partners including InSphero, as part of the European Commission EU Body on a Chip (BoC) Project. The award specifically referenced work published in July of 2015 in the Journal of Biotechnology entitled “3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis,” one of several peer-reviewed publications resulting from the project since 2014.

Dr. Frey, who recently joined InSphero to serve as Microphysiological Systems Product Manager, stated “It is a tremendous honor to receive the 3Rs Award on behalf of all of the scientists who have collaborated on the project since its inception four years ago. As an innovator in the field of 3D cell culture, InSphero was a strong commercial partner and helped keep our work focused on developing a scalable, flexible technology.”

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented, “We are delighted to have a proven leader in microphysiological systems such as Olivier join the InSphero team. His expertise and familiarity with our advanced 3D tissue models will help us accelerate commercialization of the technology, focusing on pharmaceutical and chemical industry applications that reduce both drug development costs and the need for animal testing.”

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 Frey InSphero Portrait web

Dr. Olivier Frey, recipient of the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe. Frey currently serves as Microphysiological Systems Product Manager at Schlieren, Switzerland based InSphero AG.

InSphero, US Congressional Leaders Discuss Technologies to Reduce Animal Research

US legislators and InSphero experts discuss benefits of human-derived 3D microtissues for more efficient drug development and less animal testing.

Schlieren, Switzerland - Sept 21, 2016 – InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, met with members of the United States House of Representatives last Thursday to discuss advances in in vitro research technology that can help reduce the use of animals in research. The High-Tech Health Research Expo, organized by Pennsylvania Representative Tom Marino (PA-10), gave InSphero and other life science companies the opportunity to present their technologies to Congressional leaders working to reduce the use of animal testing in the United States. PDF file

InSphero’s flagship products, 3D InSight® Human Liver Microtissues and Human Islet Microtissues, are produced using cells obtained from human donor tissue, which is broken down and reassembled into 3D microtissues using InSphero 3D Select™ Technology. Microtissues are delivered to researchers in a 96-well plate, one microtissue per well, allowing the simultaneous testing of multiple drugs on a standardized, human-derived tissue. Compared to the same cells grown in 2D, 3D microtissues more accurately reflect the native biology of in vivo human tissue, and can be cultured for over four weeks, enabling long-term testing of drug exposure over weeks instead of hours.

Dr. Jan Lichtenberg, InSphero CEO and Co-founder, says the use of more in vivo-like, human-derived 3D model systems is already making a positive impact on drug development pipelines in the pharmaceutical industry. Lichtenberg says, “Our 3D models enable researchers to verify a drug’s efficacy and predict potential toxicity and side-effects using more biologically relevant cell based assays. An additional benefit is less dependency on animal models, the use of which is not only ethically charged, but can also add significant cost, delay time to market, and often fail to accurately reflect how humans will respond to a drug.”

Congressman Tom Marino, an advocate for reducing the use of animal testing for research purposes, says the event accomplished its objective of bringing together legislators and technology providers with a common aim. Marino states, “It was a pleasure to host and recognize InSphero as one of the companies who specialize in alternative, non-animal testing methods. The more stringent restrictions on animal testing imposed in Europe helped InSphero to emerge as a leader in the field of human-based tissue models. They have now established roots in the United States, and are a leading solution provider in the global cause toward developing better drugs while using fewer animals.”

InSphero has worked actively with global organizations such as the Center for Alternatives to Animal Testing (CAAT) and the European Society for Alternatives to Animal Testing (EUSAAT) to advance the use of better in vitro models. Along with CAAT, the National Center for Advancing Translational Sciences (NCATS), and Promega Corporation, InSphero has co-organized the New Frontiers in 3D Cell Culture-based Screening Technologies Conference, which will be held October 13, 2016 in Baltimore, MD.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

Contact This email address is being protected from spambots. You need JavaScript enabled to view it. for high resolution images.

nl pic left   nl pic rightInSphero representatives meet congresswoman Dina Titus

Photo caption 1 (left)   

InSphero aims to improve in vitro testing by facilitating the development and use of organotypic 3D cell culture models for safety and efficacy testing. Top left image: InSphero’s patented GravityPLUS® Hanging Drop System. Subsequent images (in clockwise order): assay-ready 3D liver, pancreatic islet, tumor, skin, and brain microtissues.

Photo caption 2 (center)

InSphero representatives met with Congressman Tom Marino (PA-10) at the High-Tech Health Research Expo held September 15 in Washington, DC. Pictured left to right: Dr. Randy Strube (InSphero Director of Global Marketing), Congressman Marino, and Dr. Brian Manning (InSphero East Coast Director of Business Development).

Photo caption 3 (right)

InSphero representatives met with Congresswoman Dina Titus (NV-3) at the High-Tech Health Research Expo held September 15 in Washington, DC. Pictured left to right: Dr. Brian Manning (InSphero East Coast Director of Business Development), Dr. Judi Wardwell-Swanson (InSphero East Coast Field Application Scientist), Congresswoman Titus, and Dr. Randy Strube (InSphero Director of Global Marketing).

InSphero Launches 3D Mitochondrial Toxicity Testing Service

InSphero Launches 3D Mitochondrial Toxicity Testing Service

New contract screening offering combines advanced 3D liver microtissue models and Agilent XFe96 Analyzer to identify mitochondrial liabilities for drug safety testing market.

Schlieren, Switzerland, Sept 7, 2016 – InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has launched a new service, 3D InSight™ Mitochondrial Toxicity Testing, for the identification of mitochondrial liabilities during drug development and safety testing. Data characterizing the mitotoxicity assay was presented Tuesday at EUROTOX 2016, the 52nd Congress of the European Societies of Toxicology.  PDF file

Mitochondrial toxicity is a major adverse mechanism of toxicity for many drugs assigned black box warnings. When cells encounter stress, such as exposure to toxic drugs, they utilize reserve respiration capacities, which are quantified in the assay as spare respiratory capacity (SRC). A decrease in SRC is one of the first detected consequences of mitochondrial impairment, and the assay compares dose-dependent changes in SRC and cellular viability to assess the likelihood a drug will impair mitochondrial function.

The new service combines the organotypic liver functionality and 28-day in vitro lifespan of 3D InSight™ Human Liver Microtissues with state of the art analysis of mitochondrial respiration using the Agilent XFe96 Analyzer. The long-term metabolic competence of 3D liver microtissues enables flexible drug exposures of up to 14 days, while the XFe96 Analyzer allows assessment of mitochondrial function through sensitive and precise measurement of cellular oxygen consumption rate (OCR) on a single microtissue level.

Dr. Jens M. Kelm, InSphero Chief Technology Officer and Co-founder, says the service capitalizes on the in vivo-like biology of 3D human liver microtissues. Kelm says, “Mitochondrial SRC serves as the cell’s energy safety net, a reserve that helps cells respond to stress. When grown in 3D, primary human liver cells have a 4-times greater SRC than when grown in 2D. Using 3D microtissues in the assay not only enables us to expose primary human liver cells to drugs for up to 14 days, but also to measure the drug’s impact on mitochondria in a model that more accurately reflects the cellular response to stress in vivo. By comparing the cellular viability to the mitochondrial function after drug treatment, we can determine if mitochondrial impairment is more likely the primary mechanism of toxicity, or rather a secondary effect.”

A tutorial featuring the 3D InSight™ Mitochondrial Toxicity Service is scheduled to appear in the September 15th issue of Genetic Engineering and Biotechnology News (GEN). It is the latest addition to InSphero’s suite of 3D InSight™ In Vitro Toxicology Services, utilized by the world’s largest pharmaceutical and chemical companies to evaluate drug safety.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Schlieren, Switzerland, July 13, 2016 – Inaugural meeting, organized by InSphero AG, NCATS, CAAT, and Promega Corp., to be held Thursday, October 13, 2016 in Baltimore, MD.  PDF file

Registration and abstract submission for the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies: Towards greater physiological relevance conference open today via the conference website. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corp., the conference will feature keynote presentations by Dr. Michael Gottesman of the NIH’s National Cancer Institute’s Center for Cancer Research, and Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT.

The one-day symposium, to be held Thursday, October 13, 2016 at the Johns Hopkins University Charles Commons in Baltimore, Maryland, will feature sessions on drug discovery and toxicology, with invited presentations from Novartis, the Hubrecht Institute, Merck, and the NIH’s National Institute of Environmental Health Sciences (NIEHS). Additional speakers will be selected from attendee abstracts submitted for podium presentation, with abstracts for consideration due by August 1, 2016. Abstracts for poster presentations will be accepted until August 15, 2016.

Dr. Jens Kelm, Chief Scientific Officer of InSphero AG and member of the New Frontiers Scientific Advisory Board, says the conference fills what has been a clear gap in scientific forums by focusing on a global view of 3D cell culture technologies. “The goal of this new conference is to assemble an international forum of leaders in the field of 3D tissue models. We aim to offer a balanced perspective of state-of-the-art systems, their adoption and implementation in drug discovery and safety testing, and potential regulatory hurdles to consider as 3D models become standardized and more mainstream.” Kelm notes that the New Frontiers Conference plans to alternate between US and European host cities on an annual basis.

To register or receive more details about the conference, visit the New Frontiers in 3D Cell Culture-based Screening Technologies website.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

InvitroCue Commences Pancreatic Toxicity Assay Development

Logo

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. This builds on a previous MOU between InSphero and InvitroCue on the in vitro cell-based hepatotoxicity assay. PDF File

InvitroCue has a history of pioneering technology and establishing industry firsts for liver-related testing assays through its partnerships with leading pharmaceutical and biotech companies. As part of InvitroCue’s objective to cater for increasing demand for more innovative products and services it has also introduced disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis, malaria and perfused human liver tissue. The strategic partnership with InSphero demonstrates the company’s ongoing commitment to deliver customer-centric innovation and best-in-class technological solutions.

“We aim to offer a convenient assay solution for our biopharmaceutical customers to accelerate preclinical anti-diabetic drug development and assessment of potential pancreatic toxicities associated with their metabolites,” commented Dr. Steven Fang, Executive Director of InvitroCue.

InSphero CEO and co-founder Dr. Jan Lichtenberg said, “The collaboration allows InvitroCue to leverage our next-generation 3D InSight™ Islet Microtissues as part of their toxicity testing services, and establishes important inroads as we continue to grow our business in the important Asia-Pacific Market.”

 

For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
This email address is being protected from spambots. You need JavaScript enabled to view it.


About InvitroCue

InvitroCue is an Australian-based biotechnology and life science services company. The Company focuses on the commercialisation of its analytics services using cell-based model and imaging based technology. Its cell-based services enable pharmaceutical and cosmetics companies to refine their drug, ingredient, compound or vaccine discovery efforts. Its digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online Web-based portal. It provides products and services in the field of in vitro drug metabolism and pharmacokinetic (DMPK), in vitro toxicology and digital pathology utilizing cell-based models and analytics. It offers image analytics services for liver disease applications. InvitroCue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). InvitroCue has been developed and validated in collaborations with leading pharmaceutical companies and scientific collaborators. InvitroCue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com

Nature Scientific Reports Publication Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Schlieren, Switzerland, June 16, 2016 – Liver spheroids display longer culture lifetime, liver-like functionality, and increased sensitivity for detection of hepatotoxic drugs.  PDF Version

Research published by the Karolinska Institute and collaborators as part of the European Community Innovative Medicine Initiative project (MIP-DILI) offers further, independent verification of the utility and promise of 3D liver microtissues for studying liver function, liver diseases and long-term drug-induced liver injury (DILI). The research was published last month in Nature Scientific Reports, an open-access journal.

The paper demonstrates the extended in vitro lifetime and organotypic characteristics of primary human hepatocytes (PHH) when cultured in a scaffold-free 3D configuration, displaying viability and liver-like functionality for up to five weeks in culture. Proteomic analysis revealed that inter-individual variability was retained between spheroids generated from different individual hepatocyte donors. The study also used the prolonged in vitro lifespan of 3D cultured hepatocytes to perform chronic exposure testing of known DILI-inducing drugs, and found they could predict toxicity at clinically-relevant doses. In addition, the spheroid model system proofed to be suitable for studying liver diseases such as cholestasis and steatosis.

Commenting on the publication, Dr. Jens M. Kelm, Chief Scientific Officer and co-founder of InSphero AG says the paper, “Reinforces to the scientific community the benefits of 3D liver microtissues for the purpose of safety assessment during drug development. 3D liver models show enhanced culture lifetime in comparison to standard 2D cultured hepatocytes. This allows for long-term, repeat dose exposure studies, and enhances the sensitivity and predictive power of the model.”

InSphero uses its patent-pending 3D Select™ Process to enable industrial-scale production of 3D liver microtissues for in vitro liver research and DILI testing conducted by the world’s largest pharmaceutical and chemical companies. Dr. Kelm notes that InSphero has performed similar proteomic and genomic characterization of its 3D InSight™ Human Liver Microtissues grown over 28 days in culture, results presented at the EuroTox Annual Meeting in 2015. InSphero’s 3D Select™ Process yields liver microtissues with consistent morphology and viability by ensuring only the healthiest cells incorporate into tissues, a critical difference from conventional methods. “Cryopreserved hepatocytes contain large numbers of necrotic and functionally compromised cells. This percentage varies greatly between donor lots and vendors, making it challenging to make uniform microtissues in the numbers needed for industrial-scale testing. Through our 3D Select™ Process, we remove these compromised cells prior to the aggregation step, making microtissue formation more reliable, while improving morphology and viability. This translates to a more robust, mechanistically accurate in vitro model that enables testing standardization across multiple sites, and across the industry as a whole.”

To find out more about 3D InSight™ Human Liver Microtissues, the 3D Select™ Process, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

EY World Entrepreneur Of The Year™ 2016: Dr. Jan Lichtenberg to represent Swiss entrepreneurs

ey logo detail

InSphero CEO, Dr. Jan Lichtenberg has been nominated to represent Swiss entrepreneurs at EY World Entrepreneur Of The Year™ 2016 in Monte Carlo. The winner will be announced on 11 June 2016.

pic Jan for PRZURICH, 6 JUNE 2016 – EY World Entrepreneur Of The Year™ is a global platform that highlights the great importance of entrepreneurs in every economy. Each year, a distinguished international jury selects the best of the best from a field of more than 60 nominated winners of national Entrepreneur of the Year competitions. Based on the criteria of entrepreneurial spirit, financial performance, strategy, impact on the global and local environment, innovation and personal integrity and social commitment, the jury evaluates who has ultimately set global standards from a personal and entrepreneurial standpoint.

Read full press release in English

Read full press release in German

Read full press release in French

More about the EY Entrepreneur Of The Year™ competition:
The Entrepreneur Of The Year competition has been held in Switzerland since 1998, with around 45 entrepreneurs nominated each year. In 2008, a Swiss entrepreneur was named World Entrepreneur Of The Year™ when Dr. Jean-Paul Clozel, founder and CEO of Actelion Pharmaceuticals Ltd. won the award.

 

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

Schlieren, Switzerland, March 16, 2016 – 3D human liver microtissues comprised of pooled hepatocytes from multiple donors offers more genetically diverse model for DILI detection and prediction.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, today announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The newest liver model is being introduced at the Society of Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana. Failure of drugs during late phases of the drug discovery process costs the pharmaceutical industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to accurately distinguish between known hepatotoxicants and structurally-related non-toxic analogs. The new multi-donor microtissues offer the same structural and functional robustness of single-donor microtissues, but provide a more diverse genetic background to help mitigate bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome P450 enzymes.

Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes from 5 male and 5 female donors, multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of cells for microtissue production. This makes them an ideal tool for in vitro DILI detection and prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”

Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with Kupffer cells, enabling detection of immune-mediated toxicity.

To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Images

multi donor modified2 no backgroundmulti donor icon balanced5

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

Schlieren, Switzerland, February 10, 2016 – Latest update of industry manual for development of high-throughput screening calls on scientists from leading 3D cell culture provider for standardized viability, toxicity protocols.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has contributed a chapter in the NIH National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual, which describes best practices for adapting and standardizing high-throughput assays for use with 3D microtissues. The chapter, “In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays,” was co-authored by Dr. Monika Kijanska and Dr. Jens M. Kelm of InSphero, and appears in a 2016 update to the eBook published last week.

Dr. Terry Riss, Global Strategic Marketing Manager, Cell Health at Promega Corporation, and a contributing editor for the Assay Guidance Manual states, “The new chapter by Drs. Kijanska and Kelm provides expert guidance for scientists moving into the realm of using more physiologically relevant 3D cell culture model systems, and fills a long overdue gap in the content of the Assay Guidance Manual.” Dr. Kelm, Chief Scientific Officer and co-founder of InSphero said, “It was an honor to lend our expertise to such a well-recognized and widely accepted reference guide for cell-based assay and screening communities. It’s a great example of open innovation.” The chapter addresses considerations for choosing an appropriate 3D model, provides guidance on selection of reagents and protocol adaptations proven to work in a 3D setting, and gives specific examples of cell viability and toxicity assay results obtained with InSphero 3D InSight™ Human Liver Microtissues and Tumor Microtissues.

Early iterations of the manual were created by staff researchers at Eli Lilly and Company, but content for the Assay Guidance Manual is currently edited by 19 researchers representing 11 institutions, including NCATS and Lilly. The manual provides guidelines for scientists in academic, non-profit, government and industrial research interested in developing assays useful in screening molecules that modulate biological targets, pathways, or cellular phenotypes. Such molecules may serve as candidates for development of novel drugs for diseases such as cancer, diabetes, neurodegenerative disease, and rare genetic disorders.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

Schlieren, Switzerland, February 01, 2016 – US subsidiary of Swiss-based InSphero AG initiates direct product shipments, progresses towards full-scale US bioproduction capabilities.. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has begun accepting orders and processing all financial transactions with customers in North America through its US subsidiary InSphero Inc. The February 1 transition immediately streamlines access to InSphero products and services for US-based customers, and positions the company to initiate operations in its recently completed US bioproduction laboratory in Brunswick, Maine.

Stewart Hunt, General Manager of InSphero Inc., states the transition, “Will dramatically simplify order fulfillment for customers in our largest market by allowing them to order directly from a US source. This eliminates customs processing, additional handling fees, as well as potential delays encountered by those currently using shipment brokers to manage direct international purchases.

The transition accompanies another milestone for InSphero Inc., which has assembled an expert team of 11 US-based employees over the past year. Says Hunt, “We’ve moved quickly, adding key scientific staff to lead the laboratory build-out, technology transfer, and initiate product manufacturing in our state-of-the-art Brunswick facility. Concurrently we have established an experienced team of sales managers, field application scientists, marketing, and product management professionals to provide responsive education and support to our North American customers.”

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stewart Hunt
General Manager, InSphero Inc
Phone +1 800-779-7558 ext. 101
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

Schlieren, Switzerland, January 25, 2016 – Study describes high-throughput compatible screening assay using 3D tumor microtissue models to classify efficacy, toxicity, and mechanism of action for compounds in NIH Oncology Library. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologietransfer GmbH, at today’s annual meeting of the Society for Laboratory Automation and Screening (SLAS) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens M. Kelm during Monday afternoon’s Assay Development & Screening poster session.

InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating highly biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than traditional 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines with stromal fibroblasts were generated using InSphero’s patented hanging drop technology. Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration confirmed more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues than to the same cells grown in monolayer. Furthermore, the screen identified three compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking heterogeneous tumor microenvironments when conducting such high-throughput in vitro screens. Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens.

“Here we’ve established a multi-parametric phenotypic screening method that not only factors in tumor size and cell viability, but also discriminates between anti-tumor and non-specific toxic effects of compounds. Using these results, we can determine a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.” In addition to Dr. Kelm’s poster presentation, InSphero microtissues and high-throughput screening and imaging concepts will be featured during several events at SLAS2016, including two exhibitor tutorials and other collaborative posters.

For more information about NCATS, visit www.ncats.nih.gov.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Dr. Jens M. Kelm
Chief Scientific Officer and Co-founder
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

InSphero Adds Head of Sales, Expands Global Sales Team

InSphero Adds Head of Sales, Expands Global Sales Team

Schlieren, Switzerland, January 21, 2016 – Beate Schnell, Ph.D. joins senior team at global leader in 3D cell culture, announces new hires to support US and European growth. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has appointed Dr. Beate Schnell to serve as Head of Sales. Dr. Schnell joins the InSphero senior management team having previously held senior-level strategic sales, sales operations, and key account management positions at Promega Corp., Promega GmbH, and Abbott Diagnostics. 

InSphero CEO and co-founder Dr. Jan Lichtenberg states the addition of Schnell “adds instant energy and over 15 years’ experience in the global life sciences research and diagnostics industry to lead our growing global sales team.  Beate brings with her a proven track record of setting and achieving ambitious sales objectives with one of our industry’s leading companies, and her scientific background and customer-centric sales focus make her a natural fit for InSphero.  We are excited to have her leading our team and driving our coordinated sales and marketing initiatives.” 

Along with the hiring of Schnell, InSphero’s sales team and facilities are expanding to meet increased demand within the US marketplace where InSphero’s  assay-ready 3D InSight™ Microtissues and contract screening services are gaining traction for safety and efficacy testing within the pharmaceutical industry.  States Lichtenberg, “In addition to Beate, we’ve recently added experienced regional account professionals and field application scientists in the US and Europe.  With the establishment of our US bioproduction facility in Brunswick, Maine, we have created capacity to provide responsive, best-in-class product delivery and support to our North American customers.”   

BSc

 

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

InSphero goes Greener

Product manuals to be delivered as digital documents

InSpheroFlashDrive

As part of our ongoing corporate initiative to be an environmentally responsible, "green" company, InSphero will begin delivering product manuals and other relevant technical documents in electronic format. Beginning in January 2016, product shipments will include an e-document-packed USB flash drive containing relevant product manuals and technical protocols. The most current version of technical documents, as well as product literature and application notes, will continue to be available for download on the support section of the InSphero website.

We need your help!
Your feedback and suggestions are important to us! Please help us continue to improve the quality of our products and customer support. Submit your feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. or complete our plate feedback survey: https://www.surveymonkey.com/r/platefeedback

Tissue Engineering Publication Features InSphero Cardiac Microtissues

Tissue Engineering Publication Features InSphero Cardiac Microtissues

 

A recent paper from our collaborators at Bern University Hospital and Cellular Dynamics International (CDI), published in Tissue Engineering Part C: Methods, compares cardiomyocytes derived from iPSCs grown in traditional 2D cell culture to 3D cardiac microtissues formed using InSphero hanging drop technology. Their results show that 3D cardiac microtissues are free of necrosis and recapitulate vital cardiac functions, making them an ideal model system for testing new therapeutic strategies and detecting cardiotoxicity. 



Learn more about novel applications of 3D cardiac microtissues in development at InSphero:

View a complete list of InSphero Publications

InSphero Granted Hanging Drop Patent in United States

InSphero COO Melanie Aregger Receives 2015 Women's Business Award

InSphero COO and Head of InSphero Diagnostics Melanie Aregger recieves 2015 Women's Business Award "Megatrend Health"

Congratulations to InSphero COO and Head of InSphero Diagnostics Melanie Aregger, who on Tuesday, November 10 was honored with the 2015 "Megatrend Health" Women's Business award at the Women's Business Conference of the University of Lucern. Melanie Aregger was one of ten honorees at the 10th annual event, whith the guiding theme "visibility" of women in the economy and leading positions.

2015 07 16 13 22 58 AVScrollView 2

 

Interview with Melanie Aregger (German)

The keynote was opened by Swiss Federal Council Doris Leuthard, followed by discussions about institutional and media visibility, as well as personal visibility and self-branding.
Highlight of the event was the presentation of the ten winners of the Women's Business Award 2015. "Interesting women, which have, in representation of many others, achieved something extraordinary, something different and new. We want to give visibility to those achievements and person behind it" as project leader Sita Mazumder of the University of Lucern says.

University of Lucern press release (German)

More about the Women's Business Conference

Want to hear more InSphero success stories? Sign up for our newsletter or follow us on Twitter and LinkedIn

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Promotes Melanie Aregger to Chief Operating Officer

InSphero Promotes Melanie Aregger to Chief Operating Officer

Schlieren, Switzerland, November 24, 2015 – Head of InSphero Diagnostics division and senior team member promoted to assume role as COO. PDF Version

InSphero AG the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer.

Having joined InSphero in November 2013 as Business Development Manager, Ms. Aregger served on the management team and was promoted to Head of InSphero Diagnostics in 2014.  There she has built up the InSphero Diagnostics business unit, while assisting in the securing of Series C financing for InSphero AG, a round which netted CHF 20MM in July 2015. Her efforts in these responsibilities recently earned Melanie the 2015 Women’s Business Award by “Megatrend Health.”  In her new role as COO she will continue to drive the Diagnostics business as part of her business development responsibilities and also manage InSphero’s operations, purchasing and bioproduction functions. 

InSphero CEO and co-founder Dr. Jan Lichtenberg states, “With her entrepreneurial business acumen and profound professional experience including business-model analysis, change and risk management, supply-chain optimization and product launches, Melanie Aregger has been a key member of the InSphero management team for the past two years. Her leadership as COO will continue to benefit our global growth initiatives in both the drug-testing and diagnostics markets.”

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

A Network Sets Things in Motion: TEDD Celebrates its 5th Anniversary

At the Annual Meeting at ZHAW Waedenswil on 22 October 2015, the TEDD-Network (Tissue Engineering for Drug Development and Substance Testing) celebrated its 5th anniversary. Since its foundation, TEDD has become an internationally renowned competence centre and includes currently 91 members from academia and industry. They cover the entire development and value chain. 

“Coming together is a beginning, keeping together is progress; working together is success”. This comment of the American industrialist Henry Ford inspired Professor Ursula Graf- Hausner, Head of Research of Cell Culture Technology and Tissue Engineering at ZHAW Waedenswil, when in 2010 she founded the TEDD network together with InSphero AG, Swiss leading supplier of organotypic in vitro 3D micro tissues for drug testing. Convinced of the TEDD concept, Gebert Ruef Foundation funded the first steps.

Read full article

more about TEDD

TEDD Quote Jens

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero CEO Jan Lichtenberg Receives EY Entrepreneur of the Year "Emerging Entrepreneur" Award

InSphero CEO and co-founder Jan Lichtenberg receives Swiss "Emerging Entrepreneur" award from EY. 

Congratulations to InSphero CEO and co-founder Dr. Jan Lichtenberg, who on Friday, October 23 was honored as the 2015 Swiss "Emerging Entrepreneur" at the EY Entrepreneur of the Year™ 2015 award ceremony held in Zurich, Switzerland.  Dr. Lichtenberg was one of four honorees at the 18th annual event, which also recognized the top Swiss entrepreneurs in Trade/Services, Industry/High-Tech/Life Sciences and Family Business categories. 

Ernst & Young press release:

Dr. Jan Lichtenberg: Building bridges with an eye for revolutions

The "Emerging Entrepreneur" category always features surprising entrepreneurs who dare to reconsider conventional practices and look at new ideas as the rule rather than the exception. In all economic sectors, this continually leads to useful innovations that make progress for the entire industry, and not just for the emerging entrepreneurs' companies. A great example is Dr. Jan Lichtenberg, who has won the award for Entrepreneur Of The Year 2015 in this category. With his biotech company InSphero AG, he aspires to bring about a revolution in testing practices in drug development, using his systems and materials to bring greater efficiency, reliability and effectiveness to the testing process. Organotypic 3-D micro-tissues are the centerpiece of the InSphero revolution. The jury was fascinated by the opportunities offered by Dr. Lichtenberg's innovation, and was impressed by his ability to concentrate the focus of a diverse, international research team of top specialists to target a common goal and stay on course. What's more, he also communicates eye-to-eye with investors. Dr. Lichtenberg is an entrepreneur of international standing and global potential, so it is no surprise that he can count himself among the winners of the Entrepreneur Of The Year award in 2015.

InSphero press release

JLi EY2015

Watch EY portrait video

Connect: https://twitter.com/EY_EOY

Want to hear more InSphero success stories? Sign up for our newsletter or follow us on Twitter and LinkedIn

 

 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

 

Schlieren, Switzerland, Oct 21, 2015 –In a large (€ 30 MM) H2020-supported collaborative project, leading cell culture technology provider joins consortium to jointly foster more efficient, animal-free chemical safety assessment.  PDF Version

InSphero AG, the leading provider of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has been awarded € 750K in funding over six years as part of the € 30 MM EU-ToxRisk collaborative project funded by Horizon 2020.

An international consortium of 39 partner organisations will be funded by the European Commission to work on the integration of new concepts for regulatory chemical safety assessment. These new concepts involve cutting-edge human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular mechanistic understanding of toxicity into safety testing strategies. The ultimate goal is to deliver reliable, animal-free hazard and risk assessment of chemicals

Coordinated by Bob van de Water, Professor of Toxicology at the University Leiden (The Netherlands), EU-ToxRisk has the ambition to become the flagship in Europe for animal-free chemical safety assessment. The project will integrate advancements in cell biology, omics technologies, systems biology and computational modelling to define the complex chains of events that link chemical exposure to toxic outcome. The consortium will provide proof of concept for a new mechanism-based chemical safety testing strategy with a focus on repeated-dose systemic toxicity as well as developmental and reproductive toxicity. Importantly, novel mechanism-based test methods will be integrated in fit-for-purpose testing batteries that are in line with the regulatory framework and will meet industrial implementation. EU-ToxRisk will develop new ab initio quantitative risk assessment approaches based on understanding of so-called “Adverse Outcome Pathways” incorporating all mechanistic toxicity data available in the public domain. It will also achieve a rapid improvement of so-called “read across” approaches as the most important data-gap filling and hence animal-saving alternative method at present. Thus, the project strives towards faster safety evaluation of the many chemicals used by industry and the society.

InSphero CSO and co-founder Dr. Jens Kelm says the award, “serves as a key indicator of the value being placed on advanced 3D models in the project, as they provide greater longevity to enable repeat-dose testing in vitro, and improved biological relevance and mechanistic accuracy relative to traditional 2D cell culture models.   Much of the in silico and predictive modelling algorithms are based upon large amounts of data accumulated using 2D models, so 3D microtissues stand to be a valuable resource in helping to update and refine that data to increase its predictive value.  We are excited to lend our expertise in developing and producing a diverse range of organotypic microtissues, implementing state-of-the-art 3D optimized assays, and integrating microtissues into Body-on-a-Chip systems to advance the aims of the consortium.” 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Oliver Krähenbühl Named as InSphero CFO

Addition of internationally experienced finance manager strengthens senior team.

InSphero announced today that Oliver Krähenbühl has been hired to serve as Chief Financial Officer. Mr. Krähenbühl joins the InSphero senior management team having previously held CFO positions at HF Global Inc. New York, Canon, and JobCloud AG, the leading Swiss online professional recruiting company.  Read the press release

Portrait Juli 2015

 

InSphero Granted Hanging Drop Patent in United States

Publication: Adding the 'heart' to hanging drop networks for microphysiological multi-tissue experiments.

Beating cardiac microtissues added to hanging drop BoC networks.

Researchers at the ETH Zurich have added beating cardiac microtissues developed by InSphero into a novel microfluidic device that can synchronize the beating microtissue with unidirectional pulsed- or continuous flow of culture medium throughout an interconnected hanging drop microtissue network. Read the full article describing this next-generation Body-on-a-Chip concept published in the Sept 15 issue of the journal Lab on a Chip (open access until November 19, 2015), and read the feature article on the publication in Chemistry World.

Synchronously beating neonatal rat cardiomyocytes in 3D:

 

Learn more about cardiac microtissues:

Poster: Transmembrane Potential Measurements in Cardiac Microtissues Derived from Human Stem Cells

Webinar: Introduction to Cardiac Microtissues and Assaying Electrical Activity, Intracellular Calcium and Contractility in Cardiac Microtissues Using CellOPTIQ Platform from Clyde Biosciences 

 

More information about InSphero products and services 

 

InSphero Granted Hanging Drop Patent in United States

InSphero Launches 14 Day Hepatotoxicity Testing Service

Service offers convenient monthly runs at $990 per compound to streamline DILI testing in 3D primary human hepatocytes

As part of our growing portfolio of in-house standardized 3D InSight™ testing services, InSphero has launched a 14 Day Hepatotoxicity Testing Service to simplify DILI testing in patent-pending 3D InSight™ Human Liver Microtissues.  At just $990 per compound, customers receive repeat-dose 14 day toxicity assessment in primary human hepatocyte/Kupffer cell co-culture microtissues, with results returned three weeks after the initial dosing.  IC50 dose-response curves are delivered for the test compound(s) as well as vehicle control and two positive controls (Chlorpromazine and Ketoconazole) using the Promega CellTiter-Glo® Cell Viability Assay (measuring total spheroid ATP content).  Monthly runs initiate on the first Tuesday of every month beginning November 3 and December 1, 2015.   

How will your compounds perform in 3D? 

Click here for details, or contact This email address is being protected from spambots. You need JavaScript enabled to view it. to request a quote or place an order. 

14 day your compound here

InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

Schlieren, Switzerland, September 29, 2015 – Patent establishes protection of InSphero GravityPLUS™ technology in all major global markets, key milestone for leading provider of 3D cell culture platforms, microtissues and services.  PDF Version

The United States Patent and Trademark Office (USPTO) officially granted InSphero AG full protection of its GravityPLUS™ hanging drop technology.  InSphero, the world's leading developer of easy-to use solutions for organotypic 3D cell culture models and body-on-a-chip systems, now holds hanging drop patents in the world's major pharmaceutical and biotechnology markets, including the United States, Europe, China, Japan, and Singapore. The core patent WO2010031194 describes multi-well plates which allow the generation of hanging drops for 3D cel culture, using convenient top loading of the cell suspension.

InSphero commercialized the hanging drop technology as the GravityPLUS™ Hanging Drop System in 2010.  The system includes the GravityPLUS™ plate used for production of 3D spheroids in hanging drops, and also the companion GravityTRAP™ culture and assay plate, to which 3D microtissues are transferred for long-term culture and drug testing. 

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the favorable decision has been a long time coming for InSphero.  “We are excited the USPTO has recognized the originality of our design, and granted protection of the investment we have made into the creation of new technology.  This protection allows us to operate unhindered in the US market, gives our customers there added confidence to invest in InSphero technology as their platform of choice for 3D cell culture, and provides the grounds necessary to defend against industry competitors attempting to imitate our technology.”

Granting of the patent on September 8 followed InSphero’s recent completion of a Series C financing round , and August announcement naming PerkinElmer as the exclusive global distributor of InSphero hanging drop and ultra-low attachment (ULA) plates for 3D cell culture. 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

AstraZeneca to present pancreatic microislet data at EASD Annual Meeting

AstraZeneca to present pancreatic microislet data at EASD Annual Meeting 

EASD2015

The 51st annual European Association for the Study of Diabetes (EASD) meeting will take place in Stockholm, Sweden September 14-18.  It is the largest international scientific meeting on diabetes and its complications.  One of the more than 1200 abstracts being presented this year will feature work performed by AstraZeneca's Dr. Eva-Marie Andersson and colleagues using InSphero 3D InSight™ Pancreatic Microislets.  You can view the abstract entitled "Human pancreatic microislets as a standardised model for glucose stimulated insulin and glucagon secretion" on the EASD virtual meeting website.

Learn more about our long-lived, standardized 3D islet model system for diabetes and metabolism research by visiting the product page, or viewing our on demand webinar: 3D InSight™ Human Pancreatic Microislets and the Combined Power of HTRF® Technology.

Human Islets

    

InSphero 3D Cell Culture Platforms Now Available Exclusively Through PerkinElmer

PE Announcement

The GravityPLUSTM Hanging Drop System and GravityTRAPTM ULA Plates are now EXCLUSIVELY available through PerkinElmer  

We are excited to inform you that InSphero and PerkinElmer have entered into a partnership making PerkinElmer the exclusive global distributor of our GravityPLUSTM and GravityTRAPTM 3D cell culture plates.  Read the Press Release

Our partnership with PerkinElmer will help make our industry-leading GravityPLUSTM Hanging Drop System and GravityTRAPTM ULA Plate technologies more readily available to a global customer base and simplify logistics associated with world-wide ordering and delivery.  We assure you that PerkinElmer will honor you as their customer in the same way we have, and that their products will bring added value to your 3D cell culture research.

Beginning July 21, 2015 we ask that you please place orders for InSphero plates through PerkinElmer. Please read the attached bulletin closely for a list of affected InSphero products and the new PerkinElmer part numbers, along with answers to Frequently Asked Questions about placing orders through PerkinElmer.

Other 3D InSightTM products from InSphero are not affected by this distribution agreement, therefore please continue to order assay-ready 3D microtissues, cell culture media, assay kits and services directly through InSphero.

In case of any remaining questions, kindly contact This email address is being protected from spambots. You need JavaScript enabled to view it.

InSphero Secures CHF 20 Million Series C Financing

InSphero AG Secures CHF 20 Million Series C Financing

fireworks 260x180

Celebratory fireworks may be the July theme in the United States and France, but InSphero's securing of CHF 20 million in Series C financing from WILD Group Management LLC, is triggering pyrotechnic-worthy celebration in Schlieren, Switzerland as well.  The recently finalized investment, announced in Wednesday's press release, is being used to rapidly expand InSphero's global footprint and broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing. 

InSphero CEO Dr. Jan Lichtenberg says, "this investment is an affirmation of InSphero's valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process," and is a direct result of the growing adoption of InSphero's 3D models by major pharma companies since 2014. 

Read the entire press release here, and thank you to all of our dedicated employees, loyal customers, strategic business partners, and key investors for helping us achieve the latest milestone in InSphero's rapidly evolving success story! 

Replay NOW: InSphero 3D Summer School Webinar Series 2015

2015 InSphero Summer School2

InSphero 3D Summer School Webinar Series 2015 - A great way to learn how 3D cell culture is simply more relevant!

InSphero's 2015 3D Summer School Webinar Series was back by popular demand! We had expanded this unique online event series to help you keep in touch with the latest in 3D cell culture technology and applications during summer time. A great opportunity to learn in an online format, making it easy to attend topics of greatest interest to you!

From basic 101 classes on 3D cell culture, to advanced sessions focused on cancer biology, toxicology and more, our 2015 webinar series gathered high-quality speakers and participants from industry and academia spanning a wide range of 3D knowledge and experience. 

Replay

Want to be among the first to know about upcoming webinars? Sign up for our newsletter

July 27 - August 7 - InSphero 3D Summer School Webinar Series 2015

2015 InSphero Summer School2

InSphero 3D Summer School Webinar Series 2015 - A great way to learn how 3D cell culture is simply more relevant!

InSphero's 2015 3D Summer School Webinar Series is back by popular demand! We've expanded this unique online event series to help you keep in touch with the latest in 3D cell culture technology and applications during summer time. This is a great opportunity to learn in an online format, making it easy to attend topics of greatest interest to you!

From basic 101 classes on 3D cell culture, to advanced sessions focused on cancer biology, toxicology and more, our 2015 webinar series gathers high-quality speakers and participants from industry and academia spanning a wide range of 3D knowledge and experience. Attend one or attend them all at no cost.

  • 1+ webinar per day over 2 weeks
  • Presentations from 3D cell culture and application experts from industry, academia, InSphero and our partners
  • Topics from general overviews to specific applications for safety, efficacy, and disease modeling

Date: Monday, July 27 to Friday, August 07, 2015

 

Registration now open!

Planned Webinar Topics Include:

  • An introduction to 3D cell culture techniques and the benefits of scaffold-free systems
  • 3D optimized endpoints and cell based assays for spheroid analysis
  • Metabolic profiling of 3D microtissues
  • 3D tumor models for drug discovery
  • High throughput size profiling of tumor spheroids  
  • 3D liver microtissue models for toxicity testing
  • High content imaging of liver microtissues  
  • 3D pancreatic, cardiac, and neuronal model systems for toxicity testing and disease modeling
  • The Body on a Chip - modeling complex multi-organ systems using microtissues and microfluidics  


Earn your InSphero Ph.3D. and get the chance to win a $500 travel grant!
 

1230028 Green Mortar Board Graduation Cap Icon

  • Attend any 4 InSphero 3D Summer School sessions, and you'll earn a unique InSphero Ph.3D. diploma!
  • Attend 5 or more InSphero 3D Summer School sessions and qualify for the Grand Prize drawing of a $500 travel grant to a 2015 or 2016 meeting hosted by one of the following:
    AACR
    EORTC
    SOT
    ESTIV
    InSphero User Group Meeting

  • Can't attend that many sessions? No worries, you'll still have a chance to win! For each 3D Summer School session you attend, your name will be entered into a drawing to win 1 of 5 revolutionary SWATCH SISTEM51 series watches in the color of your choice. The more you attend, the more you learn...and the better your chance of winning!
  • Want to be among the first to know about upcoming webinars? Sign up for our newsletter

SOLD OUT - InSphero UK User Group Meeting

 UGM UK Banner

 

Register NOW! 

2015 InSphero UK
User Group Meeting

 


Limited seating available.

Date: 11 June, 2015

Venue: The Trinity Centre, Cambridge

sout

Please put me on the waiting list!*

* the waiting list will be considered if a registered participant will cancel his participation prior to the User Group Meeting. Slots will be filled according to the date of the e-mail sent to us with a request to be placed on the waitinglist. For questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.


Current Agenda

 


10:00 - 10:30       Welcome Reception and Introduction
                                by Tony Rutt of InSphero


10:30 – 11:00      3D InSightTM Services Overview
                               by Dr. Johannes Haugstetter of InSphero


11:00 – 11:30     Compound Classification Strategies Using Homo- 
                               and Heterotypic Tumor Microtissues
                               by Zoe Weydert, Master of Science at Zurich 
                               University of Applied Sciences (ZHAW)


11:30 – 12:00     Applications of in vitro assays to measure cellular 
                               response in 3D cell cultures 
                               by Dr. Marta Rucka of Promega

12:00 – 13:00      Networking Lunch incl. Live Demonstration

13:00 – 13:30      Understanding Cellular Metabolism of Spheroids 
                               Using Extracellular Flux Technology 
                               by Dr. Alex Liversage of Seahorse Bioscience
 

13:30 – 14:00      Use of Liver Microtissues for Drug Safety 
                               Assessment: an AstraZeneca Perspective 
                               by Alison Foster of Astra Zeneca

14:00 - 14:15       Short Break
  
14:15 – 14:45      Optical measurements of electrical activity and 
                               contraction from cardiac microtissues of 
                               iPS-derived cardiomyocytes
                               by Dr. Maria Hortigon, University of Glasgow 
                               and Clyde Biosciences Ltd., UK


14:45 – 15:15      Proteomic Profiling of 3D Human Liver
                               Microtissues
                               by Dr. Claudia Escher of Biognosys


15:15 – 16:00      Wrap up & Networking Coffee
                               by Tony Rutt of InSphero

 

 

Want to be among the first to know about future UserGroup Meetings? Sign up for our newsletter

 

 

27.04.2015 - Register NOW for the InSphero & Promega User Group Seminars

InSphero Promega WS

InSphero & Promega User Group Seminars

3D Cell Cultue Model Systems & Cell-based Assays for Use with 3D Cultures. 

User Group Seminar Berlin 

Monday, May 4, 2015, 14:00 - 16:00 in Berlin 

Find out more: Seminar Berlin

Register here!

User Group Seminar Munich

Monday, May 11, 2015, 14:30 - 16:30 in Munich

Find out more: Seminar Munich

Register here!

GEN Tutorial Quantifies BSEP and MRP2 Activity in 3D Liver

Our latest tutorial "Quantifying Efflux Activity in 3D Liver Spheroids" in Genetic Engineering and Biotechnology News (GEN) highlights the use of 3D InSightTM Human Liver Microtissues to assess bile salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2) activity using fluorescent probes quantified with the PerkinElmer Opera PhenixTM High Content Screening System. 

Read the tutorial or learn more about 3D InSightTM liver microtissues

 GEN tutorial

CFDA staining of bile canaliculi in 3D InSightTM Human Liver Microtissues visualized in the PerkinElmer Opera PhenixTM

13.04.2015 - InSphero User Group Meeting, Zurich NOW open for registration

UGM ZH Banner

Register NOW! Seats still remain for the 2015 InSphero UserGroup Meeting in Zurich, Switzerland.

Register here: https://www.eventbrite.com/e/insphero-user-group-meeting-zurich-registration-15613687961

Registration deadline: May 18 or as soon as fully booked

Agenda:

08:30 - 09:00       Welcome Reception and Introduction by Dr. Jan Lichtenberg, CEO InSphero AG, Switzerland

09:00 – 09:30      3D InSightTM Liver Microtissues by Dr. Simon Messner, InSphero AG, Switzerland

09:30 – 10:00      3D InSightTM Services Overview by Dr. Johannes Haugstetter, InSphero AG, Switzerland

10:00 – 10:30      Testing Biologicals Using 3D Microtissue Models by Dr. Jens Kelm, InSphero AG, Switzerland

10:30 – 11:00      Coffee Break incl. Live Demonstration

11:00 – 11:30      Compound Classification Strategies Using Homo- and Heterotypic Tumor Microtissues
                               by Zoe Weydert, Master of Science at Zurich University of Applied Sciences (ZHAW)


11:30 – 12:00      Cell-Based Assays for more than Monolayers by Dr. Reka Nagy, Promega AG, Switzerland

12:00 – 13:00      Networking Lunch

13:00 – 13:30      Global Proteonic Profiling of 3D Human Liver Microtissuesby Dr. Claudia Escher, 
                                Biognosys AG, Switzerland


13:30 – 14:00      Imaging Bile Canaliculi in 3D InSightTM Human Liver Microtissues Using the Opera PhenixTM High 
                               Content Screening System by Dr. James Hutt, PerkinElmer, United Kingdom

14:00 – 14:30      Our Body on a Chip byDr Olivier Frey, ETH Zurich, Switzerland

14:30 – 15:00      Coffee Break incl. Live Demonstration

15:00 – 15:30      Pancreatic Microislet Model for Glucose- Stimulated Insulin Secretion Assay  
                            
by Dr. Kristin Breitschopf, Sanofi-AventisDeutschland GmbH


15:30 – 16:00      3D Microtissues Are Relevant Models to Investigate Target Genes and Therapeutic Approaches for Breast 
                               Cancer by Dr. Nataša Anastasov, Helmholz Center Munich, Germany 


16:00 – 17:30      Wrap Up & Networking Reception by Dr. Jan Lichtenberg, CEO InSphero AG, Switzerland

 

Find out about the upcoming UserGroup Meeting in the UK, June 11, 2015 here

Want to be among the first to know about future UserGroup Meetings? Sign up for our newsletter

 

 

12.04.2015 - InSphero a Finalist for 2015 Export Award

slider export award S GE Award 0

We're proud to have been nominated as one of 3 finalists for the 2015 Export Award. 

Export is the backbone of the Swiss economy, with approximately 12% of Swiss companies working in the export business.  The Export Award is considered the "Oscar of the Swiss export industry".

The finalists have been chosen among all candidates for their achievement in overcoming internationalization barriers to establish business in new markets.

Winners will be announced at the Forum for Swiss Foreign Trade in Zurich on 23 April, 2015

Read the publication of the Swiss newsletter Handelszeitung here.

Learn more about InSphero, previous awards we've received or find out about the 2015 Export Award.

 

Want to be among the first to know if we won? Sign up for our newsletter

 

 

26.03.2015 - InSphero Celebrates 6 Years of Innovation

BDAY

Wednesday, March 26th marked six years since the founding of InSphero. We celebrate with a review of our top innovations from our first 6 years.

6 Years, 6 Milestones

  • 2009: 1st automation-compatible hanging-drop platform: GravityPLUS™

  • 2010: 1st dedicated assay plate for long-term assays and imaging of 3D microtissue spheroids: GravityTRAP™

  • 2011: 3D InSight™ Rat Liver Co-culture Microtissues for long-term in vitro tox

  • 2012: Portfolio expanded by 3D InSight™ Human Liver Co-culture Microtissues

  • 2013: Convenient 3D InSight™ Services including easyEST™ reproductive toxicology testing

  • 2014: 3D InSight™ Human and Rat Pancreatic Microislet models for diabetes and toxicity testing 

Want to be among the first to know about future innovations? Sign up for our newsletter, and follow us on LinkedIn and Twitter!

 InSphero- Team celebrates 6 years with a WikiDog- Lunch!

 image 29image 23image 30

17.02.2015 - Dates set for Munich, Zurich User Group Meetings

UGM Jens

Join us in Munich for our 3D Cell Culture User Group Meeting, Friday, 13 March. 

This half-day event is being held in conjunction with the Bayern Innovativ Forum Life Science 2015 in Munich, Germany.  Networking lunch included.  View the full agenda and reserve your space at this educational event featuring talks from InSphero, Promega, PerkinElmer, Seahorse Bioscience, and more. 

Save the date for Zurich - Thursday, 21 May, 2015

We're building a full-day agenda for our 5th Annual Zurich User Group Meeting to keep you updated on the latest in 3D safety and efficacy testing.  Mark your calendar and plan to join us for this educational and networking opportunity.  Learn more here

02.02.2015 - Two Publications, SLAS Presentation Feature Spheroid-based Body on Chip Strategy

Two publications in the last six weeks co-authored by InSphero, one in the Journal of Laboratory Automation and the other in the Journal of Biotechnology highlight progress in advanced Body on a Chip strategies.  The papers descibe culturing of 3D spheroids derived from multiple tissue types in two Body on Chip microchamber devices of varying complexity.  The work will be presented by InSphero's CSO and co-founder Dr. Jens M. Kelm at next week's Society for Laboratory Automation and Screening (SLAS) meeting in Washington, DC . 

The Journal of Biotechnology paper, published January 12, describes the basic design by which 4 3D spheroids can be cultured in non-adherent chambers and interconnected via microfluidic channels using a gravity-driven (rocking) action to drive flow of culture medium between chambers.  As proof-of-principle validation, liver and tumor microtissues were interconnected and treated with the anti-cancer drug cyclophosphamide (CP), a drug which requires pro-activation by the liver.  CP displayed enchanced anti-cancer activity on tumor spheroids when connected to chambers containig liver microtissues compared to tumor microtissues treated with CP alone. 

The Journal of Laboratory Automation paper, published last month, describes a standardized 96-well format Body on Chip system that can connect up to 66 microtissues, 11 channels containing 6 chambers each.  Primary rat liver microtissues were cultured over 8 days, and multiple HCT116 tumor microtissues were dosed with the chemotherapeutic drug 5-fluorouracil (5FU) for platform characterization.    

 

21.01.2015 - 3D Liver Spheroids in Use by MIP-DILI Project

If your New Year's Resolution was to upgrade your in vitro model system to 3D, look no further than MIP-DILI for further justification to get moving on that goal.  At last fall's EUROTOX meeting, early-phase results were presented from the Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury (MIP-DILI) project.  Following the presentation, MIP-DILI has indicated 3D spheroids will be used against a panel of other in vitro test systems aimed at developing novel preclinical tests to improve drug safety testing (read the press release). 

MIP-DILI is a European consortium of industry, academic, and small/medium-sized enterprises that includes major pharmaceutical industry contributors AstraZeneca, Abbott, Bristol Myers Squibb, GSK, Merck, Sonofi and others.

Early project work involved phenotypic characterization and drug sensitivity testing of a variety of liver cell sources, including primary human hepatocytes, HepG2 and HepaRG cell lines, as well as genetically modified primary human hepatocytes.  Their findings identified primary human hepatocytes (PHH) as the key cell source to be utilized for development of preclinical test systems capable of better predicting DILI.     

Further evaluation of different culture methods of PHH included static 2D culture, perfusion cultures, fiber bioreactors and 3D spheroids.  The 3D spheroids emerged as the most metabolically competent, robust and economical model system, which will be utilized for further in-depth characterization and mechanism-based DILI testing. 

InSphero 3D InSightTM Liver Microtissues are produced using primary human hepatocytes and NPCs, delivering metabolic competency conveniently to your lab in assay-ready 96-well format.  Learn more about how our state-of-the-art, organotypic model systems can upgrade your in vitro toxicity and DMPK studies. 

 

canaliculi CDFA

Image: Organotypic bile canaliculi networks in a 3D InSightTM Human Liver Microtissue visualized using fluorescent CFDA dye.  Image courtesy of Perkin Elmer.

19.01.2015 - InSphero nanoparticle tox publication one of "most social" PFT articles

We published...you shared!

Last October, we featured a news item featuring our Particle and Fibre Toxicology publication featuring the use of 3D InSightTM Human Liver Microtissues to explore nanoparticle toxicity.  This week, the article "Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model" was noted by the journal as one of the four most socially shared articles of 2014, as announced by BioMed Central in the journal's newsletter on January 19th, 2015.  

If you were one of the many who passed the article along to a colleague, thank you!  If you didn't get a chance to read the article, here's another chance to read this share-worthy publication.

 

16.12.2014 - 2015 Desktop Calendar: "Grow With Us in 2015"

Our 2015 desktop calendar features 12 beautiful images, including hanging drops and a variety of microtissues.  Didn't get yours yet?  Visit us at spring conferences and fairs in 2015 to get one before they are all gone! 

Calendar2015 260x180

January - Bile canaliculi (brown) visualized in 3D InSight™ Human Liver Microtissues stained with anti-BSEP antibody.  Photo by Dr. Simon Messner, InSphero AG.

February - This mid-aggregation heart-shaped rat cardiac microtissue, derived from neonatal rat primary cardiomyocytes took the term “organotypic” to the next level! See video of beating tissues here. Photo by Dr. Irina Agarkova, InSphero AG.

March - Immunofluorescent staining of H292 tumor microtissue penetrated for 30 min. with anti-human beta-integrin antibody. Anti-beta-integrin antibodies (green), actin filaments (red), nuclei (blue). Photo by Dr. Irina Agarkova, InSphero AG.

April/Cover - Hanging drops formed in the InSphero GravityPLUS™ 3D cell culture and assay platform facilitate high throughput, automation-compatible, and scaffold-free production of 3D microtissues. Photo by Rene Pretot.

May - Human keratinocyte/dermal fibroblast co-culture. Photo by Dr. Jens M. Kelm, InSphero AG.

June - CFDA staining reveals intact bile canaliculi networks in 3D InSight™ Human Liver Microtissues. Image courtesy of PerkinElmer.  Read the application note here

July - Immunofluorescent staining of 3D InSight™ Rat Brain Microtissues at day 5 of culture for GFAP (green) and beta-III tubulin (red). Nuclei stained with DAPI (blue). Photo by Seddik Hammad, IFADO Dortmund.

August - Confocal image of HCT116 colorectal carcinoma microtissues penetrated with anti-beta-integrin antibodies. Antibeta-integrin antibodies (green), actin filaments (red), nuclei (blue). Photo by Dr. Irina Agarkova, InSphero AG.

September - Light-sheet microscopy of 3D InSight™ HepG2 Liver MicrotissueLiver Microtissue. Image courtesy of Nariman Ansari, Francesco Pampaloni and Ernst H. Stelzer, Goethe University.

October - SEM image of human cardiac microtissue, seeded on fibronectin coated glass coverslips. Image courtesy of Dr. Christian Zuppinger, Bern University.

November - Immunofluorescent staining of 3D InSight™ Human Pancreatic MicroisletsPancreatic Microislets, displaying expression of insulin (green, beta cells), glucagon (red, alpha cells), and somatostatin (blue, delta cells) in various islet cell sub-types. Photo by Dr. Wolfgang Moritz, InSphero AG.

December - 3D modeling of microganglia composed of embryonic-derived sensory neurons. Sensory neurons self-assemble in fibroblast (shown in red) co-cultures into ganglia-like structures (shown in green). Photo by Dr. Jens M. Kelm, InSphero AG.

 

02.12.2014 - Holiday Production Schedule and Business Hours

To help you plan your experiments for December and January, our microtissue production calendar has been updated to reflect the impact of the Holidays on regular shipment schedules. 

Last date for 2014 microtissue shipments:

US - December 15, 2014
Europe - December 16, 2014

First date for 2015 microtissue shipments:

US - January 12, 2015
Europe - January 14, 2015

If you have a special request for shipments during this time period, please let us know as soon as possible, and we will do our best to accommodate your request.  For questions, contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Holiday business hours:

InSphero offices will be closed December 25 thru January 2.  Season's Greetings and a Happy New Year from our team to yours! 

 

20.10.2014 - New Publication Explores Nanotoxicology in 3D Liver Microtissues

Increased public and occupational exposure to nanomaterials (NM) has increased the urgency of identifying potential detrimental NM-related health consequences, including in primary NM inhalation and ingestion routes, as well as in the liver following NM translocation. This recent publication, co-authored by InSphero, explores toxicity in 3D InSight™ Human Liver Microtissues of single or multiple exposure of a panel of engineered NMs (Ag, ZnO, MWCNT and a positively charged TiO2), and demonstrates the 3D model is an excellent candidate for replacement of traditional in vitro single cell hepatic models and further progression of liver nanotoxicology.

Read the article (open access).

More InSphero publications.

20.10.2014 - Webinar to Feature Mass Spec Assessment of Acetaminophen Toxicity

Finding the Balance: Setting Up Data Independent Acquisition on a Q Exactive HF MS Using Spectronaut and Application to a Hepatotoxicity Study

This webinar, in two parts, will cover the development of an optimized Data Independent Acquisition (DIA) workflow for a proteomics study using the Thermo Scientific™ Q Exactive™ HF mass spectrometer and Spectronaut™ software. In the first part, Yue Xuan will introduce the Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer featuring an ultra-high-field Orbitrap analyzer, which doubles its speed and resolution. The benefits of fast scan speed, high mass accuracy, and excellent HCD MS/MS spectra quality of QE HF MS for DIA applications are reviewed along with a demonstration of the workflow strategy using data from analysis of various samples.

In the second part, Lukas Reiter will present DIA for protein profiling of human 3D liver microtissues on a Q Exactive HF MS and using the Spectronaut™ software. The microtissues were exposed to biologically relevant concentrations of Acetaminophen and measured in triplicates. With the instrumentation and software advancements it became feasible to robustly profile thousands of proteins across dozens of conditions with reasonable time, cost and very limited starting material.

Register for the webinar.

 

07.10.2014 - InSphero Wins 2014 ACES Life Sciences Award

InSphero earned its second major startup award in three weeks when it was named the winner of the 2014 ACES Life Sciences Award on October 7th, 2014 (Read the press release).   The ACES are the only pan-European award recognizing enterprise in university and public research institutes.  Melanie Areggar accepted the award on behalf of InSphero at the awards ceremony held at the Technical University in Berlin, Germany.  The honor follows InSphero's being named the #1 Swiss Startup in the Top 100 Swiss Startups Rankings, announced on September 18th.  The ACES awards program was created in 2008 by Science|Business, a Brussels- and London-based media company and innovation network set up to recognize academic entrepreneurship.  The winners were chosed by the Science|Business Innovation Board from a shortlist drawn up by a jury drawn from academia, industry, and venture capital. 

ACES-winner-2014-InSphero

Melanie Aregger (2nd from left) of InSphero AG accepted the 2014 ACES Life Sciences Award in Berlin, Germany on October 7th, 2014

17.09.2014 - InSphero Named #1 Swiss Startup for 2014

Logo2014

InSphero, a spin-off of the ETH Zurich and the University of Zurich, was recognized as the #1 company in the Top 100 Swiss Startups Rankings.  The award marks the fourth consecutive year that InSphero has made the Top 10 in the rankings, but is the first time the company has reached the pinnacle as the top startup across all industries.  The rankings are determined by a panel of 100 experts from the Swiss startup scene, and again recognized InSphero's continued growth and innovation as the world leader in 3D cell culture technology for safety and efficacy testing. 

15.09.2014 - InSphero Tutorial Featured in GEN

GEN-logo

The Drug Discovery section of the September 15 issue of GEN featured an InSphero tutorial "Phenotypic Drug Discovery in 3D."  The article describes the label-free assessment of HCT-116 tumor spheroid growth in response to treatment with Docetaxel and Gemcitabine using the SCREEN Cell3iMager.  Read the full tutorial on the GEN website.

For more information about the Cell3iMager, you can view the product video, watch our on-demand webinar and download application notes on the imager product page support section. 

12.09.2014 - Dates Set for US User Group Meetings

insphero ugm uk

Dates and locations have been finalized for our US user group meetings!  Each meeting will feature two topic-focused half-day workshops, with Toxicology in the AM and Oncology in the PM.  Register for one or both sessions based on your interests.  A combined networking lunch is included for both sessions.  There is no cost to attend but registration is required.  Space is limited, so click the links below for more information and to reserve your seat today!

San Francisco, CA - Friday, October 24th

Boston, MA - Thursday, November 20th 

If you are attending the ISSX/JSSX meeting in San Francisco (Oct 18-23), or the FAST meeting in Boston (Nov 17-19), extend your stay a day and join us for these exciting educational opportunities!  

05.08.2014 - InSphero to Present iPS-Derived 3D Brain Model

Brain

InSphero will present progress on an iPS-derived 3D brain model at the Cellular Dynamics 2014 European User Group Meeting being held in London, UK on October 6th.  The workshop, entitled "Advances in Human iPSC-derived Cell Models for Phenotypic Screening & Toxicity Studies" is a free multi-session conference with speakers from industry and academia using CDI's iCell(R) technology in their research.  View the full agenda, and register to attend here

31.07.2014 - InSphero Bikes Almost Once Around Switzerland

Switzerland

This year again, InSphero joined the popular Swiss-wide June "Bike to Work" campaign, and pedaled a total of 1490 km.  We didn't quite make it, but that's more than 3/4 of the way around Switzerland's external border, which stretches 1899 km.  The annual campaign put more than 50,000 people on their saddles who covered a total of 7,802,243 km, or some 4108 times around the country!   

30.07.2014 - ESACT to Host 'Cells for Compound Screening' Course

ESACT

The European Society for Animal Cell Technology (ESACT) will hold a training course for lab managers, scientists, post-docs, PhD students and engineers from industry and academia covering the important aspects of mammalian cell based screening to identify biologically active compounds.  The course will be held focuses on cell production and use for compound screening, establishment, criteria, as well as different format and use of physiologically relevant cellular assays with good reproducibility. 

The meeting will be held October 2-5, 2014 in Llafranc, Costa Brava, Spain. 

The registration deadline is August 15, and space is limited.  View the agenda and register at the ESACT website

22.07.2014 - InSphero Announces 3D Summer School Webinar Series

Looking to build on your knowledge of 3D cell culture models and methods?  Make the most of what is left of the summer by joining InSphero experts for three new 30-minute webinars on July 29th, August 7th and August 14th.  Topics covered include pancreatic microislets, inflammation-mediated cytotoxicity, and label-free spheroid imaging.  View the full schedule and webinar details

09.07.2014 - InSphero and Protea to Combine 3D Technologies

InSphero and Protea Biosciences, Inc. have announced a collaboration that will use Protea's LAESI® 3D mass spec technology to characterize InSphero 3D InSightTM Microtissues.  Read the full media release.   

Protea LAESI 3D 90x90


02.07.2014 - InSphero a Finalist for 2014 European Academic Enterprise (ACES) Award

We're proud to have been nominated as one of 3 finalists for the 2014 European Academic Enterprise Award (ACES) in Life Sciences.  The ACES are the only Pan-European award recognizing enterprise in university and public research institutes.  Winners will be announced in Berlin, Germany on 7 October, 2014.  Learn more about InSphero, and previous awards we've received.

30.06.2014 - Body-on-a-Chip Technology Published in Nature Communications

InSphero has co-authored research published in the journal Nature Communications that demonstrates the feasibility of creating multi-tissue networks of spheroids in a hanging drop format, interconnected by microfluidic channels.  The publication is the result of our ongoing EU Body on a Chip collaboration, and is highlighted by a proof-of-concept hepatic pro-drug activation experiment displaying biotransformation of cyclophosphamide (CP) by liver microtissues and the subsequent growth inhibition of perfused HCT-116 tumor spheroids.  View the PubMed abstract.

15.06.2014 - InSphero Microtissues Featured in GEN Tutorial

As a leading provider of cell based assays to the life sciences marketplace, Promega has been a valued partner of ours in adapting and validating their assays for use with 3D microtissues.  In their recent tutorial published in Genetic Engineering and Biotechnology News, Promega discusses the nuances and importance of adapting ATP and other luminescent assays, originally developed for use with monolayers of cells, for use with 3D cell culture.  The data discussed in the article was generated using tumor microtissues grown in GravityPLUSTM hanging drop plates. 

02.06.2014 - Microtissue Production Schedule Now Online

Microtissue Schedule OnlineWe've made it easier for you to plan your next experiment using 3D InSightTM Microtissues by posting our upcoming production calendar online.  Just click on the 'Production Schedule" link on any microtissue page, and you'll find the upcoming shipping dates for liver, pancreatic microislets, brain and more.  View the schedule now


Microtissue Schedule Thumb 520x360

 




28.05.2014 - InSphero Launches 3D InSight™ Pancreatic Microislets

Human IsletsInSphero's catalog of assay-ready microtissues continues to grow with the release of new 3D InSightTM Pancreatic Microislets for diabetes, metabolism, and toxicity research.  View product details and read the media release







28.05.2014 - InSphero "Pseudo-islets" Published in Journal of Tissue Engineering & Regenerative Medicine

Human-Islets-figure-4
Our recently launched 3D InSightTM Pancreatic Microislets were characterized in the April issue of the Journal of Tissue Engineering and Regenerative Medicine.  Read the article (access required), "Improved physiological properties of gravity-enforced reassembled rat and human pancreatic pseudo-islets" and view the Microislet Media Release.

 

24.04.2014 - InSphero Publishes Tumor-stroma Model for Lung Cancer

Our recent publication in the journal PLOS One highlights a 3D tumor-fibroblast co-culture model system for non-small cell lung cancer.  Read the article and press release here.

22.04.2014 - Screen Cell3iMager Now Available

Cell3iMager
The high-resolution Cell3iMager for assessment of spheroid size and morphology is now available in Europe and North America through InSphero.  View product details 



26.03.2014 - InSphero Celebrates 5 Years of Innovation

celebration
Wednesday, March 26th marked six years since the founding of InSphero. We celebrate with a review of our top 5 innovations from the last 5 years.

Our top 5 innovations from the last 5 years

  • 1999: 1st automation-compatible hanging-drop platform GravityPLUS™

  • 2010: 1st dedicated assay plate for long-term assays and imaging of 3D microtissue spheroids

  • 2011: 3D InSight™ Rat Liver Co-culture Microtissues for long-term in-vitro tox

  • 2012: Portfolio expanded by 3D InSight™ Human Liver Co-culture Microtissues

  • 2013: Convenient 3D InSight™ Services including reproductive toxicology testing easyEST™

 

 

 

25.03.2014 - InSphero & NIH’s NCATS to Collaborate

We're teaming up with the National Center for Advancing Translational Sciences to screen 460 compounds for anti-tumor activity using 3D multi-cell type tumor spheroids.

Read the media release here.

25.03.2014 - Publication Update - 3D Tumor Model Review

This must-read review in Advanced Drug Delivery Reviews, "3D cell culture systems modeling tumor growth determinants in cancer target discovery," was recently co-authored by InSphero's Dr. Jens Kelm and Dr. Irina Agarkova.

Read the publication (access required).

See more InSphero References.

04.03.2014 - InSphero 3D InSight™ Tumor Microtissue Co-cultures featured in JBS

Research in the Journal of Biomolecular Screening co-authored by InSphero AG and the Institute of Molecular Health Sciences (Zurich) characterizes a high-throughput compatible 3D tumor model system based on InSphero's GravityPLUS™ hanging drop technology. The authors use the co-culture model and RNA interference (RNAi) to reveal differential phenotypic responses to targeted gene disruption that are dependent upon the 2D or 3D manner in which the cells are grown.

Read the publication (access required).

Read the full media release here.

See more InSphero References.

04.03.2014 - InSphero Granted Hanging Drop Patents in China and Japan

InSphero adds GravityPLUS™ patents in major Asian markets to existing European & Singapore patents, awaits decision on pending US patent.

Read the full media release here.

04.03.2014 - New application note: Robust quantification of spheroid size in minutes

Rapid and precise profiling of microtissue growthSize and morphology are important determinants to evaluate biological behavior of 3D microtissues. The Dainippon SCREEN Cell3iMager and InSphero GravityTRAP™ 3D microtissue assay format combine to provide rapid, precise profiling of microtissue growth and morphology for 96-wells in about 1 minute.

Find more in our application note.

See more InSphero application notes.

28.01.2014 - New publication reveals enhanced longevity, gene expression in 3D Rat Liver Microtissues

The development of improved in vitro liver toxicity models capable of more accurately assessing drug-induced liver injury (DILI) is in great demand. A recent research article in the Journal of Tissue Science & Engineering, co-authored by InSphero, aimed to further characterize 3D Insight™ Rat Liver Microtissues by comparing the expression and activity of key enzymes involved in cytoprotection (Nrf2-responsive genes) and glucocorticoid metabolism (GR-responsive genes) in the microtissues relative to traditional 2D sandwich cultures or cell lines. The study revealed a distinct increase in the strength and duration of Nrf2- and GR-responsive genes in 3D rat liver microtissues, indicating their utility as a more suitable model for analysis of these pathways.

Read the open access article.

Read the full media release here.

See more InSphero References.

28.01.2014 - InSphero hires new Director of Global Marketing

New Director of Global MarketingInSphero starts 2014 with a new Director of Global Marketing: Randy Strube, Ph.D. joined the company in January 2014 to strengthen InSphero's marketing team. Welcome Randy!

Read the full media release here.

28.01.2014 - InSphero CEO Jan Lichtenberg interviewed by Select Science at SLAS

Dr. Lichtenberg discusses the InSphero 3D microtissue technology and it’s applications for the screening and laboratory automation industry.

Watch video on SelectScience website.

 

Company video

company-video-inspheor